Dexamethasone 0.4 MG [Dextenza]
DrugOphthalmic Intracanalicular Insert
Other names: Dextenza
NCT Number: NCT05143281
To assess the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert in the operating room following cataract surgery/intraocular lens implant (IOL) compared to insertion 1-day post-op.
Looking for future studies?
Notify Me65 year and older
All sexes
Interventional
Phase 4
Grene Vision Group, Wichita, Kansas, United States
This is a randomized, controlled study to evaluate the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert in the operating room following cataract surgery/intraocular lens implant (IOL) compared to insertion 1-day post-op.
There will be approximately 50 eyes with two groups:
Group 1 (up to 10 eyes) will receive the insert in the lower punctum on the day of surgery in the OR.
Group 2 (up to 40 eyes) will receive the insert in the lower punctum on the day after surgery in the HOPD.
Each subject's participation is expected to last for approximately 1 month and will be required to complete five scheduled visits over the course of the study period: Baseline (Screening Visit), Operative Visit/Insertion Day (Day 0), Day 1, Day 7 and Day 30.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Are an adult subject aged 65 years or older Are planning to undergo non-complicated CCI CE/PCIOL in one or both eyes Are willing and able to comply with clinic visits and study related procedures Are willing and able to sign the informed consent form
Exclusion criteria
Have active infectious systemic disease Have active infectious ocular or extraocular disease Have unobstructed nasolacrimal duct in the study eye(s) Have known hypersensitivity to dexamethasone or are a known steroid responder Have a history of ocular inflammation or macular edema Are currently being treated with immunomodulating agents in the study eye(s) Are currently being treated with immunosuppressants and/or oral steroids Are currently being treated with corticosteroid implant (i.e. Ozurdex) Have a history of herpes simplex virus keratitis or present active bacterial, viral, or fungal keratitis in either eye Have a history of complete punctal occlusion in one or both punctum Currently use topical ophthalmic steroid medications Are unwilling or unable to comply with the study protocol Are determined by the Investigator to not be included for reasons not already specified (e.g., systemic, behavioral, or other ocular disease/abnormality) or if the health of the subject or the validity of the study outcomes may be compromised by the subject's enrollment
Ophthalmic Intracanalicular Insert
Other names: Dextenza
Time frame: Assessed on Day 7
As measured by summed ocular inflammation score (0-4 with 4 meaning a worse outcome)
Time frame: Assessed on Day 7
As measured by ocular pain assessment numerical grading scale (0-10 with 10 meaning a worse outcome)
Time frame: Assessed on Day -1, Day 7, Day 30
As measured by snellen VA
Time frame: Assessed on Day -1, Day 1, Day 7, Day 30
As measured by ocular pain assessment numerical grading scale (0-10 with 10 meaning a worse outcome)
Time frame: Assessed on Day -1, Day 1, Day 7, Day 30
As measured by summed ocular inflammation score (0-4 with 4 meaning a worse outcome)
Time frame: Assessed on Day 1
As measured by physician questionnaire
Grene Vision Group
Other
A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of Treatment With an Intracanalicular Dexamethasone (0.4mg) Ophthalmic Insert in the Operating Room Following Cataract Surgery/Intraocular Lens Implant (IOL) Compared to Insertion 1-day Post-op - The SITE Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07735000
Age Related Cataract, Cataract
Peshawar, KPK, Pakistan
View Trial DetailsNCT07605260
Cataract, Eye Diseases
Islamabad, Punjab Province, Pakistan
View Trial DetailsNCT06428955
Cataract, Eye Diseases
Indianapolis, Indiana, United States
View Trial DetailsNCT06111222
Cataract, Eye Diseases
Heidelberg, Germany
View Trial Details